

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
)
David J. BURKE et al.) Group Art Unit: 1644
)
)
Application No.: 10/773,406) Examiner: Y. KIM
)
)
Filed: February 9, 2004) Confirmation No.: 6608
)
)
For: IMMUNOGLOBULIN FORMULATION)
 AND METHOD OF PREPARATION)
 THEREOF)
)
)

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: December 15, 2006

By: 
Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

1034008-000003 0210151 0010076 1077333

DEB/YELLIN

103.32.07

**FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 1

Application Number	10/773,406
Filing Date	February 9, 2004
First Named Inventor	David J. BURKE et al.
Examiner Name	Y. KIM
Attorney Docket No.	1034008-000003

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CLELAND, Jeffrey L. et al., "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation", Critical Review in Therapeutic Drug Carrier Systems, 10 (4): 307-377 (1993).

Examiner Signature _____ **Date Considered** _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.